Navigation Links
Study Funded by National Foundation for Cancer Research Reveals Imaging Studies May Predict Tumor Response to Anti-Angiogenic Drugs
Date:11/23/2013

Bethesda, MD (PRWEB) November 23, 2013

A new report published in the Proceedings of the National Academy of Science (PNAS) Early Edition details a study funded in part by the National Foundation for Cancer Research, which indicates magnetic resonance (MR) imaging may be able to discern which patients will benefit more from anti-angiogenic drugs.

An NFCR Fellow, Rakesh K. Jain, Ph.D., is a senior author of the study and the director of the Steele Laboratory for Tumor Biology in the MGH Department of Radiation Oncology.

The just-released study shows that cancer patients with glioblastoma—the deadliest form of brain tumor— survived longer with the increased level of blood perfusion due to the anti-angiogenic agent cediranib. The level of blood perfusion was revealed using advanced brain imaging called vessel architectural imaging (VAI) and other MR imaging techniques.

This study also confirms the hypothesis Dr. Jain proposed more than a decade ago on how anti-angiogenic drugs work. These drugs enhance the activity of chemo- and radiation therapy, yet the mechanisms of their action remain unclear. Results from the study suggest that, rather than 'starving' tumors by choking their blood supply as scientists originally thought, it appears that anti-angiogenic drugs actually work through “normalizing” the abnormal, leaky blood vessels that surround the tumors. This normalization process may improve the delivery of chemotherapy drugs and the oxygen that is required for effective radiation therapy.

“This study is a turning point, as it is the result of a decade-long journey towards the confirmation that vascular normalization actually increases tumor perfusion and that increased perfusion, rather than tumor starvation, increases the likelihood of survival,” said Dr. Jain. “I am honored to be a part of this research and NFCR’s pursuit of more effective treatments for glioblastoma patients.”

“NFCR is proud to support this leading-edge research that will help increase survival rates among glioblastoma patients,” said Franklin Salisbury, Jr., President of NFCR. “Being able to improve the effectiveness of treatments for cancer patients is a stepping stone on the way towards finding a cure.”

To read the report and find out more about the study’s implications, please visit http://www.pnas.org/content/early/2013/10/31/1318022110.full.pdf+html.

About the National Foundation for Cancer Research
The National Foundation for Cancer Research (NFCR) is a leading cancer research charity dedicated to funding cancer research and public education relating to cancer prevention, earlier diagnosis, better treatments and, ultimately, a cure for cancer. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside.

Since 1973, NFCR has provided over $309 million supporting discovery-oriented cancer research focused on understanding how and why cells become cancerous, and on public education relating to cancer prevention, detection, and treatment. For more information, please visit http://www.NFCR.org.

###

Read the full story at http://www.prweb.com/releases/2013/11/prweb11364428.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Study looks at better prediction for epileptic seizures through adaptive learning approach
2. Kessler Foundation study provides first Class 1 evidence for cognitive rehabilitation in MS
3. Study shows displaying lab costs upfront can save money
4. HIV and parenting needs to be discussed, new study finds
5. New Results from an Orriant Study Illustrate Drastic Improvements Both Physically and Financially
6. Fertility Centers of Illinois is Recruiting Patients for The MultiCenter Registry with Eeva™ (MERGE) Research Study
7. Study reveals higher levels of control and support at work increases wellbeing
8. Blood vessel tangles in brain best left alone, study suggests
9. "Taking Timeout from Technology" Study Results Announced by The Unplug Series, Shows 20% Would Suffer Withdrawal Symptoms After 24 Hours
10. New Study Improves Understanding of Tinnitus Perception by Patients
11. New study finds no benefit to selecting dose of blood thinner based on patients genetic makeup
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Representatives of CHA Fertility Centers ... member of their staff, Dr. Joshua J. Berger. As of May 2016, Dr. ... world-renowned facility. , Dr. Berger has received recognition for his research, his teaching and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Horizon Blue Cross Blue Shield ... relief from the crushing burden of sky-high health care costs, Superior Court of ... ruling ( http://www.judiciary.state.nj.us/opinions/a2913-15a2929-15.pdf ) the court provided some analysis of the contracts ...
(Date:6/23/2016)... ... ... As part of an ongoing commitment to encourage living a healthy and ... BCBSNJ) have teamed up with New Jersey native and PGA Tour member Morgan Hoffmann ... lifestyle. , Through Healthy Steps NJ, Hoffmann will share a series of health education ...
(Date:6/23/2016)... ... ... A key metric of this success is the popularity of the Leafedin.org service ... areas that lack the kind of technology and networking framework that LeafedIn.org provide, where ... the marijuana industry, no matter how small or large, and more importantly no matter ...
(Date:6/23/2016)... ... June 23, 2016 , ... King Kullen’s Shop OnLine, the ... to yet another location: Garden City Park. This is the fourth store to be ... grocery delivery service is offered by King Kullen and allows customers to place orders ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: